<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A-1
(Mark One)
[ X ] Annual report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934
For the fiscal year ended JUNE 30, 1997
or
[ ] Transition report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from ____________ to ___________
COMMISSION FILE NUMBER 0-20127
ESCALON MEDICAL CORP.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER.)
California 33-0272839
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
182 Tamarack Circle
Skillman, New Jersey 08558
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 609-497-9141
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
Title of each class: Name of each exchange on which registered:
None None
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
Common Stock, without par value
Class A Redeemable Common Stock Purchase Warrants, exercisable for the purchase
of one share of Common Stock, without par value
Class B Redeemable Common Stock Purchase Warrants, exercisable for the purchase
of one share of Common Stock, without par value
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days: YES X NO
--- ---
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. /X/
The aggregate market value of the voting stock held by non-affiliates of the
registrant is approximately $2,657,434. Such aggregate market value was computed
by reference to the bid and asked price of the Common Stock in the when-issued
trading market on September 11, 1997. For purposes of making this calculation
only, the registrant has defined affiliates as including all directors and
beneficial owners of more than ten percent of the Common Stock of the Company.
The number of shares of the registrant's Common Stock outstanding as of
September 11, 1997 was 10,517,519.
DOCUMENTS INCORPORATED BY REFERENCE
None
<PAGE> 2
PART III
PRELIMINARY NOTE:
This Form 10-K/A-1 is being filed to report Part III information in
lieu of the incorporation of such information by reference to the Company's
definitive proxy material for its 1997 Annual Meeting of Stockholders.
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
DIRECTORS OF THE COMPANY
<TABLE>
<CAPTION>
YEAR FIRST BECAME DIRECTOR, PRINCIPAL OCCUPATIONS DURING
NAME OF DIRECTOR AGE PAST FIVE YEARS AND CERTAIN DIRECTORSHIPS
- ---------------- --- --------------------------------------------------------
<S> <C> <C>
Richard J. DePiano 56 Mr. DePiano has been a director of the Company since February 1996. Mr.
DePiano has been the Chief Executive Officer of the Sandhurst Company, L.P.
and Managing Director of the Sandhurst Venture Fund since 1986. Mr. DePiano
is Chairman of the Board of Directors of Surgical Laser Technologies, Inc. Mr.
DePiano has served as Chairman and Chief Executive Officer of the Company
since March 1997.
Jack M. Dodick, MD 58 Dr. Dodick has been a director of the Company since February 1996. Dr. Dodick
has served as the Chairman of the Department of Ophthalmology at Manhattan
Eye, Ear and Throat Hospital in New York since 1982.
Jay L. Federman, MD 59 Dr. Federman has served as the Chairman of the Board of Directors of the
Company since February 1996. Dr. Federman has served as the Chief of the
Division of Ophthalmology at the Allegheny University Medical College of
Pennsylvania since 1993 and as Co-Director of the Retina Service and Research
Department at Wills Eye Hospital in Philadelphia, Pennsylvania since 1980. Dr.
Federman is a director of Surgical Laser Technologies, Inc.
Robert J. Kunze 62 Mr. Kunze has served as a director of the Company since 1988. Mr. Kunze has
been a general partner of H&Q Life Science Ventures and H&Q Life Science
Technology Fund I, venture capital investment funds, since July 1987 and October
1987, respectively. Both funds were liquidated in December 1996 and,
consequently, Mr. Kunze no longer serves as a general partner of such funds.
Sterling C. Johnson 57 Mr. Johnson has been a director of the Company since February 1996. Mr.
Johnson has served as the President and Chief Executive Officer of the
Company since February 1996. From 1989 through and including the present,
Mr. Johnson has served as the President and Chief Executive Officer of EOI
Corp. ("EOI").
</TABLE>
EXECUTIVE OFFICERS OF THE COMPANY
<TABLE>
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
Richard J. DePiano 56 Chairman and Chief Executive Officer
</TABLE>
2
<PAGE> 3
<TABLE>
<S> <C> <C>
John T. Rich, C.P.A. 42 Vice President of Finance and Administration, Secretary
Ronald L. Hueneke 54 Vice President, General Manager, Trek Division
</TABLE>
Mr. DePiano's background is set forth above under "Directors of the
Company."
Mr. Rich was appointed the Vice President of Finance and
Administration, the Treasurer and the Secretary of the Company in December 1996.
From February 1996 until December 1996, Mr. Rich served as the Vice President of
Finance and Administration and the Assistant Secretary of the Company. From
January 1990 until February 1996, Mr. Rich held several senior management
positions with, and continues to serve as a vice president of, EOI. From August
1980 until January 1990, Mr. Rich was employed by Arthur Andersen & Co., an
international public accounting firm.
Mr. Hueneke was appointed a Vice President of the Company and the
General Manager of its Trek division in February 1996. From 1991 until February
1996, Mr. Hueneke held various senior management positions with EOI. Mr. Hueneke
co-founded Trek Medical Products, Inc., a vitreoretinal instrument and equipment
business, in 1983 and served as its President until October 1991 when it was
acquired by EOI.
ITEM 11. EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION
The following table sets forth certain compensation paid by the Company
to its Chief Executive Officer and certain other highly compensated executive
officers of the Company for all services rendered in all capacities for the
periods shown. This table includes Sterling C. Johnson, who stepped down from
his positions with the Company effective April 30, 1997.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG TERM
COMPENSATION
ANNUAL COMPENSATION OTHER AWARDS
------------------- ANNUAL ------------ ALL OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY BONUS COMPENSATION OPTIONS COMPENSATION(1)
- --------------------------- ---- ------ ----- ------------ ------- ---------------
<S> <C> <C> <C> <C> <C> <C>
Richard J. DePiano(2) 1997 $ 73,846 -- -- -- $ 3,200
Chairman and Chief Executive 1996 -- -- -- -- --
Officer 1995 -- -- -- -- --
John T. Rich 1997 $119,000 $14,500 -- -- --
Vice President of Finance and 1996 $ 43,858 -- -- -- --
Administration, and Secretary 1995 -- -- -- -- --
Ronald L. Hueneke 1997 $105,000 $14,500 -- -- --
Vice President, General Manager, 1996 $ 39,159 -- -- -- --
Trek Division 1995 -- -- -- -- --
Sterling C. Johnson 1997 $118,088 -- -- -- $109,832
Former President, Chief Executive 1996 $ 55,677 -- -- -- $ 2,536
Officer and Chief Operating Officer 1995 -- -- -- -- --
</TABLE>
3
<PAGE> 4
(1) Includes payment by the Company of (i) in the case of Mr. Johnson (a)
$60,000 in earned but unpaid compensation pursuant to Mr. Johnson's employment
agreement (see section entitled "Employment Agreements" herein for a
description of Mr. Johnson's employment agreement); (b) an automobile allowance
in the amount of $4,971; (c) $7,244 in insurance premiums paid for life
insurance; (d) severance payments in the amount of $23,697; and (e) accrued
vacation pay in the amount of $13,920, paid upon Mr. Johnson's retirement from
the Company and (ii), in the case of Mr. DePiano, an automobile allowance in
the amount of $3,200.
(2) Mr. DePiano became Chairman and Chief Executive Officer of the Company on
March 1, 1997.
OPTION GRANTS IN LAST FISCAL YEAR
<TABLE>
<CAPTION>
% OF POTENTIAL REALIZABLE
TOTAL OPTIONS VALUE AT ASSUMED
GRANTED TO ANNUAL RATES OF STOCK
OPTIONS EMPLOYEES IN EXERCISE PRICE EXPIRATION PRICE APPRECIATION FOR
NAME GRANTED(1) FISCAL YEAR $/SHARE) DATE OPTION TERM(2)
---- ---------- ----------- -------- ---- --------------
5% 10%
-- ---
<S> <C> <C> <C> <C> <C> <C>
Richard J. DePiano............ 450,000 100% $0.563 6/4/07 $159,330 $403,775
John T. Rich.................. -- -- -- -- -- --
Ronald G. Hueneke............. -- -- -- -- -- --
Sterling C. Johnson -- -- -- -- -- --
</TABLE>
(1) These options were granted under the Company's 1993 Stock Option Plan
and have a term of ten years, subject to earlier termination in certain
events. See "Employment Agreements." The options are fully vested.
(2) The potential realizable values are based on an assumption that the
stock price of the Common Stock starts equal to the exercise price
shown for the particular option grant and appreciates at the annual
rate shown (compounded annually) from the date of grant until the end
of the term of the option. These amounts are reported net of the option
exercise price, but before any taxes associated with exercise or
subsequent sale of the underlying stock. The actual value, if any, an
option holder may realize will be a function of the extent to which the
stock price exceeds the exercise price on the date the option is
exercised and also will depend on the option holder's continued
employment through the vesting period. The actual value to be realized
by the option holder may be greater or less than the values estimated
in this table.
AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION VALUE
<TABLE>
<CAPTION>
NUMBER OF VALUE OF
UNEXERCISED UNEXERCISED IN-THE-
OPTIONS AT MONEY OPTIONS AT
JUNE 30, 1997 JUNE 30, 1997(1)
------------- -------------------
SHARES ACQUIRED VALUE
NAME ON EXERCISE REALIZED EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ---- --------------- -------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
Richard J. DePiano -- -- 450,000 -- $41,850 --
John T. Rich -- -- -- -- -- --
Ronald L. Hueneke -- -- -- -- -- --
Sterling C. Johnson -- -- -- -- -- --
</TABLE>
- -------------------
(1) Potential unrealized value is (i) the fair market value at fiscal 1997
year-end less the option exercise price times (ii) the number of
options. Fair market value as of fiscal 1997 year-end was determined
based on a closing sale price on June 30, 1997 of $0.656.
NO AWARDS WERE MADE TO ANY NAMED EXECUTIVE OFFICER DURING SUCH FISCAL
YEAR UNDER ANY LONG-TERM INCENTIVE PLAN. THE COMPANY DOES NOT SPONSOR ANY
DEFINED BENEFIT OR ACTUARIAL PLANS AT THIS TIME.
4
<PAGE> 5
EMPLOYMENT AGREEMENTS
On June 4 , 1997, the Company entered into an employment agreement with
Richard J. DePiano as the Chairman and Chief Executive Officer of the Company.
The term of the employment agreement commenced on March 1, 1997 and shall
continue through February 28, 1998 subject to any extensions that may be entered
upon the written agreement of the Company and Mr. DePiano. The agreement
provides for a base salary of $240,000 per year plus incentive compensation in
the form of a cash bonus to be paid by the Company to Mr. DePiano in the event
the Company has entered into a sale, license or other transfer of all or a
substantial portion of the assets of the Company, a merger or consolidation of
the Company or a sale of all or a substantial portion of the Company's capital
stock. The bonus to be paid to Mr. DePiano shall be equal to 10% of the increase
in the market capitalization of the Company as a result of any of the
aforementioned transactions from March 1, 1997 to the close of business on the
date on which Mr. DePiano's employment with the Company terminates; provided,
however, that the minimum bonus to be paid to Mr. DePiano as the result of the
Company entering into any of the aforementioned transactions shall be $250,000.
The agreement also provides that the amount of the bonus is to be reduced by an
amount equal to the appreciation value of the stock options granted to Mr.
DePiano that have theretofore been exercised or that are exercisable. Under the
terms of the employment agreement, Mr. DePiano received options to purchase
450,000 shares of the Company's Common Stock. The options granted to Mr. DePiano
are fully vested but terminate upon the payment of his aforementioned incentive
compensation. The agreement also provides for health and long term disability
insurance and other fringe benefits as well as an automobile allowance of $800
per month.
John T. Rich entered into an employment agreement with EOI in January
1990 that, as amended in January 1990 and September 1995, provides, among other
things, for annual salary at a rate established by the Company's Board of
Directors which is currently set as $119,000 per annum. Mr. Rich's employment
agreement was assumed by the Company in connection with the Assets Sale and
Purchase Agreement dated February 12, 1996 (the "Asset Sale and Purchase"),
pursuant to which EOI transferred substantially all of its assets and certain
liabilities to the Company in consideration of the issuance to EOI of 4,770,772
shares of the Common Stock of the Company. The agreement also provides for
health, life and long-term disability insurance and other fringe benefits. If
Mr. Rich is terminated without cause, the agreement provides for the
continuation of Mr. Rich's salary and fringe benefits for one year after
termination. Under the agreement, Mr. Rich was also granted options to purchase
up to 50,000 shares of the EOI's Common Stock at an exercise price per share of
$.25. The options are fully vested and currently exercisable. The employment
agreement expires in January 1998.
Ronald L. Hueneke entered into an employment agreement with EOI in
October of 1991 that provides for annual salary at a rate established by the
Company's Board of Directors which is currently set as $105,000 per annum. Mr.
Hueneke's employment agreement was assumed by the Company in connection with the
Asset Sale and Purchase. The agreement also provides for health, life and
long-term disability insurance and other fringe benefits. In addition, the
agreement provided for incentive compensation equal to 3 1/3% of the gross sales
derived from the sale by Mr. Hueneke of certain products during the initial term
of the employment agreement. Under the agreement, Mr. Hueneke was also granted
options to purchase up to 75,000 shares of the EOI's Common Stock at an exercise
price per share of $1.00. The options are fully vested and currently
exercisable. The employment agreement, which had an initial term of five years,
renews automatically from year to year unless either party notifies the other in
writing at least 90 days prior to the expiration of the then current term of its
determination not to renew the agreement.
Sterling C. Johnson entered into an employment agreement with EOI in
1989 that, as amended in January 1991 and January 1995, provided for annual
compensation in the amount of $154,000. In connection with the Assets Sale and
Purchase, Mr. Johnson's employment agreement was assumed by the Company,
including EOI's obligation to pay $60,000 in earned but unpaid compensation to
Mr. Johnson. Mr. Johnson's agreement was for a
5
<PAGE> 6
three-year term ending in December 1997 and renewed automatically for successive
one-year periods unless either party notified the other in writing at least 90
days prior to the expiration date. The agreement provided for health, life and
long term disability insurance and other fringe benefits as well as
reimbursement of the costs associated with the lease of an automobile not in
excess of $500 per month. The agreement provided for severance payments, in the
event of termination without cause, equal to Mr. Johnson's salary and fringe
benefits for one year. Mr. Johnson was granted options to purchase up to 300,000
shares of EOI common stock at an exercise price per share of $.01. The options
were exercised. Under the terms of his employment agreement, the Company was
obligated to reimburse Mr. Johnson for any withholding tax obligation and the
tax on such reimbursement in the event Mr. Johnson exercised the options.
Effective April 30, 1997, Mr. Johnson stepped down from the office of President
and Chief Operating Officer. In connection therewith, the Company made payments
to Mr. Johnson in fiscal year 1997 of $23,697 in severance payments and $13,920
in accrued vacation. The Company will have paid to Mr. Johnson the balance of
all outstanding severance-related expenses, or approximately $150,000, by the
end of April 1998.
COMPENSATION OF DIRECTORS
Messrs. Johnson, Dodick and Federman are paid directors' fees of $2,000 for
each board meeting attended in person and $500 for each Committee meeting or
meeting attended telephonically. Mr. Kunze is paid a monthly directors' fee of
$4,000 per month. In addition, directors are reimbursed for expenses incurred
in connection with attending meetings. See "Executive Officers--Executive
Compensation."
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of September 11, 1997, certain
information regarding the beneficial ownership of the Common Stock by (i) each
shareholder known by the Company to be a beneficial owner of more than 5% of the
Common Stock, (ii) each director and nominee for election as director of the
Company, (iii) each of the Named Executive Officers as such term is defined in
Item 402(a)(3) of Regulation S-K and (iv) all directors and executive officers
of the Company as a group. Pursuant to the rules and regulations promulgated
under the Exchange Act the table sets forth the most recent information provided
in filings made with the SEC by the reporting persons.
The calculation of percentage ownership as shown for each person in the
following table assumes the exercise of all options and warrants held by such
person but not the exercise of any other person's options or warrants.
Additionally, certain of the reporting persons share beneficial ownership of
certain securities of the Company. Any securities as to which beneficial
ownership is shared are set forth on the table below as beneficially owned by
each person to whom beneficial ownership may be attributed. See the footnotes to
the table for information as to shared beneficial ownership of the Company's
securities.
6
<PAGE> 7
BENEFICIAL OWNERSHIP TABLE
<TABLE>
<CAPTION>
AMOUNT OF
BENEFICIAL
AMOUNT OF OWNERSHIP OF
BENEFICIAL SHARES AMOUNT OF
OWNERSHIP OF UNDERLYING AGGREGATE AGGREGATE
OUTSTANDING PERCENT OF OPTIONS/ BENEFICIAL PERCENT
NAME AND ADDRESS OF BENEFICIAL OWNER SHARES(1)** CLASS WARRANTS*** OWNERSHIP OF CLASS
------------------------------------ ------------ ---------- ------------ ---------- ---------
<S> <C> <C> <C> <C> <C>
EOI Corp. (2)................................... 4,437,625 42.2 -- 4,437,625 42.2
182 Tamarack Circle
Skillman, NJ 08558
D. Blech and D. Blech & Company,
Incorporated (3)................................ -- -- 3,160,000 3,160,000 23.1
599 Lexington Avenue
New York, NY 10022
Allen & Company Incorporated (4)................ -- -- 635,841 635,841 5.7
711 Fifth Avenue
New York, NY 10022
R.A. Mackie & Co., L.P. (4)..................... -- -- 560,475 560,475 5.1
One Gorham Island
Westport, CT 06880
Sterling C. Johnson............................. -- -- -- -- --
Robert J. Kunze ................................ 5,759 * 5,759 5,759 *
Richard J. DePiano(5)........................... -- -- 450,000 450,000 4.1
Jack M. Dodick, M.D............................. -- -- -- -- --
Jay L. Federman, M.D............................ -- -- -- -- --
All directors and executive officers as a group
(5 persons) .................................. 5,759 * 450,000 455,759 4.2
</TABLE>
* Less than 1%.
** Includes outstanding shares owned by the named person but does not
include shares as to which such person has the right to acquire.
*** Represents shares underlying (a) Class A Redeemable Common Stock
Purchase Warrants ("Class A Warrants"), Class B Redeemable Common Stock
Purchase Warrants ("Class B Warrants") and Class C Common Stock
Purchase Warrants ("Class C Warrants"), each of which (i) entitles the
holder thereof to purchase one share of Common Stock at a price of
$6.25, $7.50 and $5.00, respectively, and (ii) was issued in connection
with a November 1993 offering; and (b) certain options, which in each
case are exercisable within 60 days from the date hereof.
(1) Except as indicated in the footnotes to this table and pursuant to
applicable community property laws, where applicable, the persons named
in the table above have sole voting and investment power with respect
to all shares shown as beneficially owned by them.
(2) As reported on Schedule 13D dated February 12, 1996 and a Form 4 dated
September 10, 1996. The outstanding share ownership set forth for EOI
consists of shares owned solely by EOI. As set forth in the Schedule
13D, Messrs. Johnson, DePiano, Dodick, and Federman are directors of
EOI. Additionally, Messrs. Johnson and Rich (the Company's current Vice
President of Finance and Administration and the Secretary) serve as the
President/Chief Executive Officer and Secretary/Treasurer/Vice
President of Finance and Administration, respectively, of EOI. Although
not currently serving as an officer of EOI, Ronald L. Hueneke, the
Company's Vice President/General Manager of Trek Division, served in
the same position for EOI prior to the Asset Acquisition. Each of the
above named individuals are also shareholders of EOI.
(3) As reported on Amendment No. 3 to the Statement on Schedule 13D dated
October 5, 1995. The ownership of shares underlying options and
warrants, as set forth for Mr. Blech, consists entirely of shares
underlying 1,380,000 Class A Warrants and 880,000 Class B Warrants
owned by Blech, and 900,000 shares subject to a Unit Purchase Option
owned by Blech (see discussion under "Certain Relationships and Certain
Transactions").
(4) For Allen & Company Incorporated such figures are as reported on
Schedule 13G dated February 14, 1997. Allen & Company Incorporated's
ownership consists of 48,646 shares of Common Stock and shares
underlying 91,805 Class A Warrants and 495,390
7
<PAGE> 8
Class B Warrants. For R.A. Mackie & Co., L.P. such figures are as
reported on Schedule 13G dated February 8, 1996 and represent ownership
of shares underlying 43,575 Class A Warrants and 516,900 Class B
Warrants.
(5) Represents 450,000 shares which Mr. DePiano has the right to acquire
upon the exercise of currently exercisable stock options.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
On February 12, 1996, the Company acquired substantially all of the
assets and certain of the liabilities of EOI, pursuant to an Assets Sale and
Purchase Agreement, in exchange for 4,770,772 shares of the Company's Common
Stock. The total estimated cost of the acquisition was $8,900,000, including
liabilities assumed (which includes the assumption of costs associated with
certain litigation involving EOI) of $1,016,340 and estimated transaction costs
of approximately $928,000. The acquisition was accounted for using the purchase
method of accounting and included the acquisition of accounts receivable,
inventories, equipment and various other tangible and intangible assets. The
total purchase price over the fair value of net assets acquired approximates
$4,100,000 and is being amortized over a ten-year period. Another $1,000,000 of
the purchase price was assigned to in-process technology and was charged to
operations immediately following the acquisition. As disclosed elsewhere herein,
Messrs. Johnson, DePiano, Dodick and Federman were at the time of the
acquisition, and continue to be, members of the Board of Directors of EOI.
Messrs. Johnson and Rich, the Company's former President/Chief Executive
Officer, Chief Operating Officer and Vice President, Finance and
Administration/Secretary, respectively, serve in similar executive level
management positions with EOI. Ronald L. Hueneke, a Vice President of the
Company and General Manager of its Trek Division, served in the same position
with EOI prior to the consummation of the Asset Acquisition. EOI is the
beneficial owner of 42.2% of the outstanding Common Stock of the Company and
each individual named in this paragraph is a shareholder of EOI.
Jay L. Federman, M.D., a Director, together with two individuals
unaffiliated with the Company, entered into a Development, Assignment and
License Agreement with the Company dated September 11, 1992. Under this
agreement, the Company has agreed to pay royalties to Dr. Federman and the two
unaffiliated individuals on sales of the Company's Iris Expander and related
products. Generally, the agreement provides for quarterly royalty payments of
10% of net sales, for sales by the Company, and the greater of 5% of net sales
or 50% of royalty payments received by the Company, for sales by sublicensees of
the Company, in countries where a valid patent for the product has issued. For
sales in countries where a valid patent has not issued, royalty payments equal
to one-half of the foregoing rates are required. As of the date hereof, the Iris
Expander is still under development. Therefore, no royalty payments have been
made to Dr. Federman or the other individuals that are parties to the
Development, Assignment and License Agreement.
Commencing November 17, 1994, upon the exercise of any Class A
Redeemable Common Stock Purchase Warrant or Class B Redeemable Common Stock
Purchase Warrant (a "Warrant"), to the extent not inconsistent with the
guidelines of the NASD and the rules and regulations of the Securities and
Exchange Commission (the "Commission"), the Company has agreed to pay D. Blech &
Company, Incorporated ("Blech"), except in certain limited circumstances, a fee
of 5% of the exercise price of such Warrant if (i) the market price of the
Common Stock is greater than the exercise price of such Warrant on the date of
exercise; (ii) on the date of exercise Blech is a registered broker-dealer and
its registration has not been suspended; (iii) such Warrant is not held in a
discretionary account; and (iv) the solicitation of such Warrant was not in
violation of Rule 10b-6 promulgated under the Securities Exchange Act of 1934,
as amended. The Company has agreed not to solicit the exercise of any Warrant
other than through Blech unless Blech is legally unable to solicit such exercise
or is prohibited from doing so by the rules of the NASD or otherwise, in which
event the Company may solicit such exercise, either itself or with the
assistance of a third party.
In November 1993, the Company sold to Blech a transferable option (the
"Unit Purchase Option") to purchase up to 300,000 Units. The Unit Purchase
Option is exercisable for a period of four years, commencing November 17, 1994,
at an initial exercise price equal to $8.00 per Unit. The Units are identical in
all respects to Units issued in an underwritten public offering of Units made in
November and December of 1993, except that (i)
8
<PAGE> 9
while the Warrants comprising such Units are held by Blech or certain
transferees of Blech, they are not redeemable by the Company and (ii) Warrants
comprising such Units are exercisable for the period commencing on November 17,
1993, and terminating at the close of business on November 24, 1994. The Unit
Purchase Option cannot be transferred, assigned or hypothecated prior to
November 24, 1994, except that it may be assigned, in whole or in part, to any
successor, officer or partner of Blech. The Unit Purchase Option contains
antidilution provisions providing for appropriate adjustment of the exercise
price and the number of Units which may be purchased upon exercise upon the
occurrence of certain events.
The Company has agreed that it will, at its expense on any one occasion
during the four-year period commencing November 17, 1994, and on any one
additional occasion at the expense of the holders thereof during such period,
register the securities underlying, or issuable upon the exercise of the
securities underlying, the Unit Purchase Option at the request of holders of a
majority of the Units issued or issuable upon exercise of the Unit Purchase
Option (including shares of Common Stock issuable upon exercise of the Warrants
included in those Units). The Company has also agreed, during the seven-year
period commencing November 17, 1994, to register on a "piggyback" basis, on an
unlimited number of occasions, such securities whenever the Company files a
registration statement.
For the life of Unit Purchase Option, the holders are given, at nominal
cost, the opportunity to profit from a rise in the market price for the
securities of the Company without assuming the risk of ownership, with a
resulting dilution in the interest of other security holders. As long as the
Unit Purchase Option remains unexercised, the terms under which the Company
could obtain additional capital may be adversely affected. Moreover, the holders
of the Unit Purchase Option may be expected to exercise such option at a time
when the Company would, in all likelihood, be able to obtain needed capital by
an offering of its securities on terms more favorable than those provided by the
Unit Purchase Option.
9
<PAGE> 10
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
ESCALON MEDICAL CORP.
(Registrant)
Dated: October 27, 1997
By: /s/ JOHN T. RICH
------------------------------------
John T. Rich
Vice President, Finance and
Administration
